| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash Flows From Operating Activities | |||||||||
Net loss | |||||||||
-26,727 | -12,189 | -12,216 | -8,332 | -11,356 | -16,073 | -4,565 | -25,527 | -11,914 | -6,814 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation and amortization | |||||||||
4,187 | 3,464 | 3,690 | 4,483 | 5,030 | 2,391 | 1,425 | 2,034 | 3,046 | 1,829 |
Deferred taxes | |||||||||
- | - | - | - | - | 5,035 | 0 | - | - | - |
Realignment accrual accretion | |||||||||
- | - | - | 34 | 139 | 142 | 142 | 142 | 161 | 147 |
Interest accretion | |||||||||
440 | 331 | 312 | 2,144 | 1,095 | 139 | 142 | - | - | - |
Bad debt expense | |||||||||
499 | - | 35 | 899 | 802 | 0 | 9 | 16 | 58 | 30 |
Reversal of DOJ accrual | |||||||||
- | -350 | - | - | - | - | - | - | - | - |
Other current assets | |||||||||
- | - | - | 102 | 979 | 0 | - | - | - | - |
Amortization of debt issuance costs | |||||||||
- | - | 117 | 0 | - | - | - | - | - | - |
Mark to market on warrants | |||||||||
-279 | 112 | 141 | 0 | - | - | - | - | - | - |
Mark to market on derivatives | |||||||||
- | - | -61 | 0 | - | - | - | - | - | - |
Gain on sale of discontinued operations | |||||||||
- | - | - | - | 21,634 | 0 | - | - | - | - |
Reversal of contingent consideration accrual | |||||||||
- | - | - | - | - | - | - | - | 1,557 | 0 |
Impairment of discontinued operations | |||||||||
- | - | - | - | - | 1,906 | 0 | - | 6,868 | 0 |
Stock-based compensation | |||||||||
1,535 | 2,270 | 1,060 | 131 | 4,017 | 2,124 | 1,723 | 1,791 | 1,936 | 1,494 |
Deferred income taxes | |||||||||
18 | - | - | 0 | -1,167 | - | - | - | - | 5 |
Change in estimate on collectability of accounts receivable | |||||||||
3,479 | - | - | - | - | - | - | - | - | - |
Reversal of severance accrual | |||||||||
- | - | -2,034 | 0 | - | - | - | - | - | - |
Non-employee share based payment | |||||||||
- | - | 216 | 0 | - | - | - | - | - | - |
Warrants issued in RedPath settlement | |||||||||
- | - | 193 | 0 | - | - | - | - | - | - |
Goodwill, Impairment Loss | |||||||||
- | - | - | - | 15,666 | 0 | - | - | - | - |
Asset impairment | |||||||||
- | - | - | 3,363 | 635 | 2,086 | 0 | 23,517 | 0 | - |
Warrant issuance | |||||||||
- | - | -2,016 | 0 | - | - | - | - | - | - |
Loss on extinguishment of debt | |||||||||
- | - | -4,278 | 0 | - | - | - | - | - | - |
Non-cash loss on debt extinguishment | |||||||||
- | - | - | - | 476 | 0 | - | - | - | - |
Change in fair value of contingent consideration | |||||||||
-44 | 1,522 | -5,602 | -11,860 | -7,993 | 0 | - | - | - | - |
Other gains and expenses, net | |||||||||
-18 | - | -5 | 4 | 0 | - | - | - | - | -16 |
Non-cash facilities realignment | |||||||||
- | - | - | - | - | - | - | 69 | 0 | 575 |
Other changes in operating assets and liabilities: | |||||||||
Increase in accounts receivable | |||||||||
961 | 3,546 | 1,228 | -4,766 | 5,486 | 3,422 | -8,256 | 1,054 | -1,397 | -2,095 |
Decrease in unbilled receivable | |||||||||
- | - | - | 16 | 181 | 0 | 6,027 | -638 | -770 | -711 |
Decrease in income tax receivable | |||||||||
- | - | - | - | - | - | - | - | - | -3,298 |
Decrease (increase) in other current assets | |||||||||
-129 | 501 | -222 | -1,478 | -2,350 | -3,678 | -1,740 | 758 | 1,797 | -327 |
Increase in other long-term assets | |||||||||
11 | - | -220 | -3,004 | -3,286 | -193 | -165 | 7 | -2,617 | 0 |
(Decrease) increase in accounts payable | |||||||||
-835 | 668 | -2,633 | 143 | 1,019 | 786 | -1,038 | -751 | 873 | 522 |
(Decrease) in unearned contract revenue | |||||||||
- | - | - | -11 | -5,201 | -929 | -5,122 | -1,381 | 2,465 | 2,625 |
Decrease in current portion of long-term debt | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Decrease in accrued salaries and bonus | |||||||||
- | - | - | -637 | 895 | -4,248 | 2,969 | -1,609 | -2,381 | 4,512 |
Increase in accrued salaries and bonus | |||||||||
482 | 30 | -1,395 | - | - | - | - | - | - | - |
Increase (decrease) in accrued liabilities | |||||||||
- | -402 | -2,751 | - | - | - | - | - | - | - |
Decrease in accrued liabilities | |||||||||
-1,341 | - | - | -4,992 | -3,389 | 1,180 | -1,805 | -5,913 | 1,817 | 5,142 |
Increase (decrease) in long-term liabilities | |||||||||
454 | -82 | 223 | -2,334 | 176 | -1,296 | -1,384 | -1,493 | -2,374 | -162 |
Net cash used in operating activities | |||||||||
-18,957 | -8,673 | -15,263 | -7,607 | -19,842 | -16,378 | -3,512 | -10,286 | 1,985 | 16,352 |
Cash Flows From Investing Activity | |||||||||
Acquisition of diagnostic assets | |||||||||
- | - | - | - | - | 8,500 | - | - | - | - |
Acquisition of Biopharma, net of cash acquired | |||||||||
13,829 | - | - | - | - | 13,359 | - | - | - | 23,912 |
Purchase of property and equipment | |||||||||
131 | 449 | 29 | 0 | 353 | 2,851 | 1,818 | 1,112 | 343 | 2,130 |
Sale of property and equipment | |||||||||
13 | - | - | - | - | - | - | - | - | - |
Loan to privately held non-controlled entity | |||||||||
- | - | - | - | - | 655 | - | - | - | - |
Net proceeds from sale of assets | |||||||||
- | - | - | - | 26,751 | 0 | - | - | - | - |
Investment in privately held non-controlled entity | |||||||||
- | - | - | - | - | - | 1,500 | - | - | - |
Net cash used in investing activity | |||||||||
-13,947 | -449 | -29 | 0 | 26,398 | -25,365 | -3,318 | -1,112 | -343 | -26,042 |
Cash Flows From Financing Activities | |||||||||
Payments of contingent consideration | |||||||||
- | - | 25 | - | - | - | - | - | - | - |
Cash received from financing arrangement | |||||||||
- | - | - | - | - | 20,000 | - | - | - | - |
Repayment of long-term debt | |||||||||
- | - | - | 1,333 | 20,000 | 0 | - | - | - | - |
Payments of contingent consideration | |||||||||
- | - | - | 475 | 0 | - | - | - | - | - |
Debt extinguishment costs | |||||||||
- | - | - | - | 1,600 | 0 | - | - | - | - |
Cash paid for debt discount and deferred financing costs | |||||||||
- | - | - | - | - | 557 | - | - | - | - |
Issuance of common stock, net of expenses | |||||||||
6,478 | - | 23,081 | 1,707 | 451 | 0 | - | - | - | - |
Issuance of preferred stock, net of expenses | |||||||||
25,744 | - | - | - | - | - | - | - | - | - |
Payment of Seller's note | |||||||||
-6,024 | - | - | - | - | - | - | - | - | - |
Borrowings on Line of Credit | |||||||||
3,000 | - | - | - | - | - | - | - | - | - |
Cash paid for repurchase of restricted shares | |||||||||
41 | - | - | - | - | - | - | - | - | - |
Exercise of warrants, net of expenses | |||||||||
- | - | 6,861 | - | - | - | - | - | - | - |
Treasury stock purchased | |||||||||
- | 9 | 28 | - | - | - | - | - | - | - |
Exercise of warrants, net of expenses | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Treasury stock purchased | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Cash paid for repurchase of restricted shares | |||||||||
- | - | - | - | 208 | 228 | 314 | 156 | 16 | 62 |
Payments for Repurchase of Common Stock | |||||||||
- | - | - | - | - | - | - | - | - | 62 |
Net cash provided by (used in) financing activities | |||||||||
29,157 | -9 | 29,889 | -101 | -21,357 | 19,215 | -314 | -156 | -16 | -62 |
Net decrease in cash and cash equivalents | |||||||||
-3,747 | - | - | - | - | - | - | - | - | - |
Net increase (decrease) in cash and cash equivalents | |||||||||
- | -9,131 | 14,597 | -7,708 | -14,801 | -22,528 | -7,144 | -11,554 | 1,626 | -9,752 |
Cash paid for taxes | |||||||||
- | 324 | 417 | - | - | - | - | - | - | - |
Cash paid for taxes | |||||||||
- | - | - | 71 | 242 | 115 | 235 | 175 | 37 | 86 |
Cash paid for interest | |||||||||
- | - | - | 0 | 3,128 | 0 | - | - | - | - |